A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
In the register
The register attaches this trial to OLX104C (OLX72021) (Olix Pharmaceuticals), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Olix Pharmaceuticals, Inc.
- Participants (registry)
- 158
- Start
- December 2025
- Primary completion
- September 2027 (planned)
- Study completion
- September 2027 (planned)
- Last registry update
- October 2026
- Countries
- Australia, New Zealand
Conditions studied: Androgenetic Alopecia (AGA)
Interventions: OLX72021, OLX72021, OLX72021, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.